Can gliotoxin, mycophenolic acid, citrinin, fumonisin B1, and nivalenol disrupt redox balance, immune signaling, mitochondrial function, or kidney function?

These five compounds can affect the specified biological systems, but their evidentiary basis and clinical context differ substantially: mycophenolic acid has a defined therapeutic immunosuppressive mechanism, whereas the mycotoxins are supported chiefly by cellular and animal toxicology.

Clinical and toxicological evidence

• Mycophenolic acid has the strongest established evidence. Its immune suppression is intentional in clinical use and results from selective inhibition of inosine monophosphate dehydrogenase (IMPDH), restricting activated T- and B-cell proliferation.
• Gliotoxin, citrinin, fumonisin B1 (FB1), and nivalenol (NIV) each produce redox disturbance, mitochondrial injury, immune/inflammatory changes, and/or renal-cell or renal-tissue injury in experimental systems. Citrinin particularly targets renal tubules; FB1 is associated with nephrotoxicity and cytokine changes; NIV has produced kidney immunopathology in mice.
• Exposure biomarkers show these mycotoxins can be encountered in humans—for example, urinary NIV was detected in 24.76% of volunteers in one Chinese study—but detection is not equivalent to demonstrated clinical toxicity.

Mechanistic explanations

• MPA: reversible, noncompetitive IMPDH inhibition depletes GMP, GTP, and dGTP, limiting DNA synthesis in lymphocytes reliant on de novo purine synthesis.
• FB1: ceramide-synthase inhibition disrupts sphingolipid metabolism, plausibly linking it to oxidative, mitochondrial, immune, and renal effects.
• Citrinin: oxidative stress, mitochondrial/calcium dysregulation, endoplasmic-reticulum stress, inflammation, and apoptosis converge in experimental renal injury.
• Gliotoxin: redox cycling and ROS-associated apoptosis can accompany mitochondrial membrane-potential loss; it also impairs calcium-dependent LC3-associated phagocytosis in macrophages.
• NIV: ROS generation and antioxidant depletion are linked to mitochondrial and DNA damage, apoptosis, and altered cytokine signaling.

Bottom line

• The overall claim is supported: each compound can disrupt at least one named function through distinct mechanisms. MPA’s immune effect is clinically established; for the four mycotoxins, the findings principally indicate experimental hazard rather than a quantified risk of these outcomes from environmental exposure in a 77-year-old man.